• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by IQVIA Holdings Inc.

    8/15/24 7:57:23 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $IQV alert in real time by email
    SC 13G 1 ef20034234_sc13g.htm SC 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ) *

    IQVIA HOLDINGS INC.


    (Name of Issuer)

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

    46266C105

    (CUSIP Number)


    August 13, 2024

    (Date of the Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed :

    ☐Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provision of the Act (however, see the Notes).



    SCHEDULE 13G
    CUSIP No. 46266C105
     Page 2 of 5 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    GIC Private Limited
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Republic of Singapore
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    6,196,441
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    2,934,055
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    6,196,441
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    2,934,055
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,130,496
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.01% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     
     

     (1) Based on 182,300,000 Common Stock outstanding as of July 16, 2024, according to the Form 10-Q filed by the Issuer with the Securities and Exchange Commission on July 22, 2024.


    SCHEDULE 13G
    CUSIP No. 46266C105
     Page 3 of 5 Pages
    Item 1(a)
    Name of Issuer

    IQVIA HOLDINGS INC.

    Item 1(b)
    Address of Issuer’s Principal Executive Offices

    2400 Ellis Rd.
    Durham, North Carolina 27703

    Item 2(a)
    Name of Persons Filing

    GIC Private Limited (“GIC”)

    Item 2(b)
    Address of Principal Business Office or, if none, Residence

    168 Robinson Road
    #37-01 Capital Tower
    Singapore 068912

    Item 2(c)
    Citizenship

    Singapore

    Item 2(d)
    Title of Class of Securities

    Common Stock, $0.01 par value per share

    Item 2(e)
    CUSIP Number

    46266C105

    Item 3
    If this statement is filed pursuant to §§240.13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

    Item 4
    Ownership

    (a - c)  The aggregate number of securities and percentage of the class of securities of the Issuer beneficially owned by the Reporting Person named in Item 2(a), as well as the number of securities as to which such person is deemed to have sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, shared power to dispose or direct the disposition, is set forth in the following tables:


    SCHEDULE 13G
    CUSIP No. 46266C105
     Page 4 of 5 Pages
    Reporting Person
    No. of Securities
    Beneficially Owned
    Percent of Class
    (3)
    Voting Power
    Dispositive Power
         
    Sole (1), (2)
    Shared (1),
    (2)
    Sole (1), (2)
    Shared (1),
    (2)
    GIC Private Limited
    9,130,496
    5.01
    6,196,441
    2,934,055
    6,196,441
    2,934,055


    (1)
    GIC is a fund manager and only has 2 clients – the Government of Singapore (“GoS”) and the Monetary Authority of Singapore (“MAS”).  Under the investment management agreement with GoS, GIC has been given the sole discretion to exercise the voting rights attached to, and the disposition of, any shares managed on behalf of GoS.  As such, GIC has the sole power to vote and power to dispose of the 6,196,441 securities beneficially owned by it.  GIC shares power to vote and dispose of 2,934,055 securities beneficially owned by it with MAS.



    GIC is wholly-owned by the GoS and was set up with the sole purpose of managing Singapore’s foreign reserves. The GoS disclaims beneficial ownership of such shares.


    (2)
    GIC disclaims membership in a group.


    (3)
    Based on 182,300,000 Common Stock outstanding as of July 16, 2024, according to the Form 10-Q filed by the Issuer with the Securities and Exchange Commission on July 22, 2024.

    Item 5
    Ownership of Five Percent or Less of a Class

    Not applicable.

    Item 6
    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

    Not applicable.

    Item 8
    Identification and Classification of Members of the Group

    Not applicable.

    Item 9
    Notice of Dissolution of Group

    Not applicable.

    Item 10
    Certifications
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     

    SCHEDULE 13G
    CUSIP No. 46266C105
     Page 5 of 5 Pages
    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as dated.


    GIC PRIVATE LIMITED
           

    By:
    /s/ Diane Liang


    Name:
    Diane Liang


    Title:
    Senior Vice President


    Date:
    August 15, 2024




    By:
    /s/ Toh Tze Meng


    Name:
    Toh Tze Meng


    Title:
    Senior Vice President


    Date:
    August 15, 2024




    Get the next $IQV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IQV

    DatePrice TargetRatingAnalyst
    4/25/2025$160.00Buy → Hold
    HSBC Securities
    4/10/2025$170.00Overweight → Equal Weight
    Barclays
    2/3/2025Buy → Neutral
    BTIG Research
    12/20/2024$250.00Overweight
    Stephens
    10/14/2024Buy
    Redburn Atlantic
    9/4/2024$275.00Outperform
    RBC Capital Mkts
    7/24/2024$266.00 → $242.00Buy → Hold
    Jefferies
    6/6/2024$270.00Buy
    Goldman
    More analyst ratings

    $IQV
    SEC Filings

    See more
    • SEC Form 10-Q filed by IQVIA Holdings Inc.

      10-Q - IQVIA HOLDINGS INC. (0001478242) (Filer)

      5/6/25 4:40:10 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

      5/6/25 7:04:26 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

      8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

      4/24/25 5:05:07 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • IQVIA downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded IQVIA from Buy to Hold and set a new price target of $160.00

      4/25/25 8:30:17 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA downgraded by Barclays with a new price target

      Barclays downgraded IQVIA from Overweight to Equal Weight and set a new price target of $170.00

      4/10/25 8:49:29 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA downgraded by BTIG Research

      BTIG Research downgraded IQVIA from Buy to Neutral

      2/3/25 8:45:01 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Annual Health Care Conference on Tuesday, May 13, 2025, at 5:20 p.m. ET (2:20 p.m. local PT). A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intellige

      5/7/25 4:15:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Reports First-Quarter 2025 Results

      Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS Revenue of $1,546 million, up 6.4 percent reported year-over-year and 7.6 percent at constant currency Operating Cash Flow of $568 million and Free Cash Flow of $426 million, up 13 percent year-over-year, representing 89 percent of Adjusted Net Income Rep

      5/6/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards

      IQVIA™ (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Marie E. Lamont, head of Real World Solutions (Patient Insights, Experience and Registry Solutions), and Dr. Joanne Hackett, vice president, Health System Services (Europe, Middle East, Africa and South Asia), have been honored by the Healthcare Businesswomen's Association (HBA). Marie has been named a Luminary, and Joanne has been recognized as a Rising Star. Marie was honored for her significant contributions to IQVIA including increasing the patient voice in research and care delivery combined wit

      4/28/25 9:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Burt Carol

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      4/25/25 6:20:48 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Danhakl John G was granted 1,592 shares (SEC Form 4)

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      4/25/25 6:20:03 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Fasano Jim

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      4/25/25 6:19:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Danhakl John G bought $255,740 worth of shares (1,275 units at $200.58) (SEC Form 4)

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      2/7/25 7:03:59 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Leadership Updates

    Live Leadership Updates

    See more
    • IQVIA Appoints Richard Staub III President of Research & Development Solutions

      IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec

      9/25/23 8:01:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions

      IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all

      6/7/22 8:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati

      3/14/22 9:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Financials

    Live finance-specific insights

    See more
    • IQVIA Reports First-Quarter 2025 Results

      Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS Revenue of $1,546 million, up 6.4 percent reported year-over-year and 7.6 percent at constant currency Operating Cash Flow of $568 million and Free Cash Flow of $426 million, up 13 percent year-over-year, representing 89 percent of Adjusted Net Income Rep

      5/6/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive

      4/21/25 4:15:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance

      Revenue of $3,958 million for the fourth quarter, $15,405 million for the full year GAAP Net Income of $437 million for the fourth quarter, $1,373 million for the full year Adjusted EBITDA of $996 million for the fourth quarter, $3,684 million for the full year GAAP Diluted Earnings per Share of $2.42 for the fourth quarter, $7.49 for the full year Adjusted Diluted Earnings per Share of $3.12 for the fourth quarter, $11.13 for the full year R&D Solutions quarterly bookings of over $2.5 billion, representing a book-to-bill ratio of 1.20x R&D Solutions contracted backlog of $31.1 billion, up 5.5 percent year-over-year at constant currency TAS Revenue of $1,658 million fo

      2/6/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by IQVIA Holdings Inc.

      SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

      8/15/24 7:57:23 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by IQVIA Holdings Inc.

      SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

      2/14/24 4:11:54 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by IQVIA Holdings Inc. (Amendment)

      SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

      1/25/24 4:59:33 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care